Use of antiepileptic drugs in pregnancy

Area of Science:

• Obstetrics and Gynecology
• Neurology
• Teratology

Background:

• Antiepileptic drugs (AEDs) are essential for managing epilepsy in pregnant women.
• Exposure to AEDs during pregnancy increases risks for major congenital malformations, cognitive impairment, and fetal death.
• Selecting the safest AED to prevent seizures while minimizing fetal risk is a critical clinical challenge.

Purpose of the Study:

• To review the differential and dose-dependent effects of various AEDs during pregnancy.
• To compare the teratogenic risks associated with different AEDs and polytherapy versus monotherapy.
• To provide recommendations for prepregnancy counseling for women with epilepsy.

Main Methods:

• Analysis of data from collaborative international registries examining AED effects in pregnancy.
• Comparison of risks for major congenital malformations, cognitive impairment, and fetal death.
• Review of existing literature on both older and newer AEDs.

Main Results:

• Valproic acid is associated with the highest risk of birth defects, particularly at doses exceeding 1000 mg/day.
• Lamotrigine may have a lower teratogenic potential, though orofacial clefts have been reported.
• AED polytherapy appears to carry greater risks than monotherapy, with limited data on newer AEDs.

Conclusions:

• Prepregnancy counseling is crucial for women of childbearing potential with epilepsy to optimize AED treatment.
• Risk assessment should consider the specific AED, dosage, and whether it's monotherapy or polytherapy.
• Further research is needed, especially for newer AEDs, to fully understand their impact on pregnancy outcomes.